查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1807350

Rozanolixizumab 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按適應症（全身性重症肌無力、其他）、按配銷通路、按地區和競爭細分，2020-2030 年預測

Rozanolixizumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Generalized Myasthenia Gravis, Others), By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 Rozanolixizumab (Rystiggo) 市值為 2.1975 億美元，預計到 2030 年將達到 5.1591 億美元，複合年成長率為 15.26%。由於自體免疫和神經系統疾病的盛行率不斷上升，需要有針對性的有效治療方案，全球 Rozanolixizumab (Rystiggo) 市場正在經歷顯著成長。單株抗體療法 Rozanolixizumab 透過選擇性抑制新生兒 Fc 受體 (FcRn) 功能，從而降低致病性 IgG 水平，為治療重症肌無力等疾病提供了一種新的作用機制。醫療保健提供者和患者對生物療法益處的認知不斷提高，再加上臨床研究的進展，正在推動生物療法的採用。製藥公司正專注於擴大其生物製劑產品組合，投資研發以最佳化療效、最大限度地減少副作用並開發患者友善的給藥方法。人們越來越重視個人化醫療，即根據患者的個人情況制定治療方案，這也推動了對 Rozanolixizumab 等創新生物製劑的需求，因為它符合複雜自體免疫疾病精準治療的趨勢。

市場概覽
預測期 2026-2030
2024年市場規模 2.1975億美元
2030年市場規模 5.1591億美元
2025-2030 年複合年成長率 15.26%
成長最快的領域 零售與電子商務
最大的市場 北美洲

關鍵市場促進因素

自體免疫疾病盛行率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

轉向標靶生物療法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球 Rozanolixizumab（Rystiggo）市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依適應症（全身性重症肌無力 (gMG)、其他）
    • 按配銷通路（醫院和專科藥房、零售和電子商務）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美 Rozanolixizumab（Rystiggo）市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲 Rozanolixizumab（Rystiggo）市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區 Rozanolixizumab（Rystiggo）市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲 Rozanolixizumab（Rystiggo）市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 Rozanolixizumab（Rystiggo）市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • UCB Pharma SA

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 30567

Global Rozanolixizumab (Rystiggo) Market was valued at USD 219.75 Million in 2024 and is expected to reach USD 515.91 Million by 2030 with a CAGR of 15.26%. The Global Rozanolixizumab (Rystiggo) Market is witnessing significant growth due to the rising prevalence of autoimmune and neurological disorders, which demand targeted and effective therapeutic options. Rozanolixizumab, a monoclonal antibody therapy, offers a novel mechanism of action for managing conditions such as myasthenia gravis by selectively inhibiting neonatal Fc receptor (FcRn) function, thereby reducing pathogenic IgG levels. Increasing awareness among healthcare providers and patients regarding the benefits of biologic therapies, coupled with advancements in clinical research, is fueling adoption. Pharmaceutical companies are focusing on expanding their biologic portfolios, investing in research and development to optimize efficacy, minimize side effects, and develop patient-friendly administration methods. The growing emphasis on personalized medicine, which tailors treatments to individual patient profiles, is also boosting demand for innovative biologics like Rozanolixizumab, as it aligns with the trend of precision therapy for complex autoimmune conditions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 219.75 Million
Market Size 2030USD 515.91 Million
CAGR 2025-203015.26%
Fastest Growing SegmentRetail & E-Commerce
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Autoimmune Disorders

The increasing prevalence of autoimmune disorders significantly drives the Global Rozanolixizumab (Rystiggo) Market, highlighting an urgent need for targeted therapeutic interventions. Generalized myasthenia gravis (gMG), a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness, affects approximately 82,715 adults in the United States as of 2021, equating to a prevalence of 37.0 per 100,000 persons. This condition predominantly impacts individuals under 50 years of age, with a higher incidence observed in females. Rozanolixizumab, an FcRn inhibitor, offers a novel treatment approach by selectively reducing pathogenic IgG antibodies, addressing the underlying pathophysiology of gMG.

Immune thrombocytopenia (ITP), another autoimmune disorder characterized by a low platelet count leading to increased bleeding risk, also contributes to the market's growth. The incidence of ITP in adults ranges from 1 to 5 per 100,000 individuals, with a higher prevalence due to the chronic nature of the disorder. These statistics underscore the increasing burden of autoimmune diseases globally, driving the demand for effective therapies like Rozanolixizumab. As the prevalence of such conditions rises, healthcare providers are seeking targeted treatments that offer improved efficacy and safety profiles, thereby propelling the adoption of Rozanolixizumab in clinical practice.

Rozanolixizumab's mechanism of action, which involves the inhibition of the neonatal Fc receptor (FcRn), allows for the selective reduction of pathogenic IgG antibodies without broadly suppressing the immune system. This targeted approach offers an alternative to conventional immunosuppressive therapies, which are often associated with broader immune suppression and significant side effects. The growing number of patients diagnosed with autoimmune conditions has led healthcare providers to seek therapies that offer higher efficacy, safety, and patient compliance, positioning Rozanolixizumab as a preferred option. Expansion of healthcare facilities specializing in chronic and complex autoimmune diseases, alongside increased access to infusion centers and specialized clinics, further supports adoption. Patient advocacy and educational initiatives are encouraging early intervention and treatment adherence, reinforcing the market demand. As autoimmune disorders continue to rise globally, the need for innovative biologics like Rozanolixizumab is expected to grow steadily, driving market expansion and creating opportunities for pharmaceutical companies to develop accessible, effective therapies for these challenging conditions.

Key Market Challenges

High Treatment Costs

A significant challenge for the Global Rozanolixizumab (Rystiggo) Market is the high cost of treatment, which can limit patient access and adoption across both developed and emerging markets. As a novel monoclonal antibody therapy, Rozanolixizumab involves complex biologic manufacturing processes, stringent quality control measures, and extensive clinical research, all of which contribute to elevated pricing. For patients, especially those without comprehensive insurance coverage or in regions with limited healthcare funding, the financial burden can be a major barrier to initiating or continuing therapy. High treatment costs may also affect healthcare providers' willingness to prescribe Rozanolixizumab, particularly when more affordable alternative therapies, such as conventional immunosuppressants or competing biologics, are available.

The pricing challenge is amplified by the chronic nature of autoimmune disorders, which often require long-term or repeated dosing to achieve sustained therapeutic outcomes. Patients may face recurring expenses, including monitoring, follow-up visits, and supportive care, which further increases the total cost of treatment. Payers and insurers may impose restrictions on coverage or require prior authorizations, delaying access and creating administrative hurdles. High costs can also influence market penetration in emerging economies, where per capita healthcare spending is limited and patients may prioritize essential medications over specialty biologics.

Companies are attempting to address this challenge through patient assistance programs, financial support initiatives, and flexible pricing strategies. Programs that subsidize out-of-pocket costs, offer co-pay assistance, or provide treatment access through specialty pharmacies can help mitigate financial barriers and encourage adoption. Despite these efforts, the high cost of Rozanolixizumab remains a critical concern for healthcare providers, payers, and patients, representing a key challenge that the market must navigate to achieve broader acceptance and sustainable growth.

Key Market Trends

Shift Toward Targeted Biologic Therapies

A prominent trend driving the Global Rozanolixizumab (Rystiggo) Market is the growing shift toward targeted biologic therapies, reflecting a broader evolution in the management of autoimmune and immune-mediated disorders. Traditional treatment options, such as corticosteroids and immunosuppressants, often affect the immune system broadly, leading to systemic side effects and variable efficacy. Rozanolixizumab, a monoclonal antibody that selectively inhibits the neonatal Fc receptor (FcRn), offers a more precise approach by reducing pathogenic IgG antibodies without compromising overall immune function. This targeted mechanism allows healthcare providers to tailor treatments to the underlying pathophysiology of specific autoimmune diseases, improving therapeutic outcomes and reducing adverse events.

The shift toward biologics aligns with increasing emphasis on personalized medicine, where therapies are selected based on patient-specific profiles, including antibody levels, disease severity, and previous treatment responses. Clinicians are adopting Rozanolixizumab as part of individualized treatment plans to optimize efficacy and safety, particularly for patients with generalized myasthenia gravis and other IgG-mediated disorders. The development of patient-friendly delivery methods, such as subcutaneous formulations, has made targeted biologics more accessible and convenient, encouraging broader adoption among both healthcare providers and patients.

Rising awareness among healthcare professionals about the benefits of FcRn inhibition, coupled with strong clinical evidence supporting Rozanolixizumab's safety and effectiveness, is reinforcing confidence in biologic therapies. Investments in research and development are further expanding the pipeline of targeted therapies, enabling treatment of a wider range of autoimmune conditions. As the healthcare industry continues to prioritize precision, efficacy, and improved quality of life for patients with chronic immune disorders, the shift toward targeted biologic therapies is expected to remain a defining trend in the Global Rozanolixizumab Market.

Key Market Player

  • UCB Pharma S.A.

Report Scope:

In this report, the Global Rozanolixizumab (Rystiggo) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rozanolixizumab (Rystiggo) Market, By Indication:

  • Generalized Myasthenia Gravis (gMG)
  • Others

Rozanolixizumab (Rystiggo) Market, By Distribution Channel:

  • Hospital & Specialty Pharmacies
  • Retail & E-Commerce

Rozanolixizumab (Rystiggo) Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rozanolixizumab (Rystiggo) Market.

Available Customizations:

Global Rozanolixizumab (Rystiggo) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Rozanolixizumab (Rystiggo) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Generalized Myasthenia Gravis (gMG), Others)
    • 5.2.2. By Distribution Channel (Hospital & Specialty Pharmacies, Retail & E-Commerce)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Rozanolixizumab (Rystiggo) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rozanolixizumab (Rystiggo) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Mexico Rozanolixizumab (Rystiggo) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Canada Rozanolixizumab (Rystiggo) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channel

7. Europe Rozanolixizumab (Rystiggo) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Rozanolixizumab (Rystiggo) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Germany Rozanolixizumab (Rystiggo) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Rozanolixizumab (Rystiggo) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Rozanolixizumab (Rystiggo) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Rozanolixizumab (Rystiggo) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Rozanolixizumab (Rystiggo) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Rozanolixizumab (Rystiggo) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Rozanolixizumab (Rystiggo) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. South Korea Rozanolixizumab (Rystiggo) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Japan Rozanolixizumab (Rystiggo) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Rozanolixizumab (Rystiggo) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Distribution Channel

9. South America Rozanolixizumab (Rystiggo) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Rozanolixizumab (Rystiggo) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Rozanolixizumab (Rystiggo) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Rozanolixizumab (Rystiggo) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Rozanolixizumab (Rystiggo) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Rozanolixizumab (Rystiggo) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Rozanolixizumab (Rystiggo) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Rozanolixizumab (Rystiggo) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. UCB Pharma S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis

16. Strategic Recommendations

17. About Us & Disclaimer